warfarin + fenofibric acid + rosuvastatin

This is a combination of three pharmaceutical agents: - **Warfarin** is an oral anticoagulant that acts as a vitamin K antagonist to inhibit the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), thereby reducing blood coagulation and preventing thromboembolic events. - **Fenofibric acid** is the active metabolite of fenofibrate and functions as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It lowers triglycerides and increases high-density lipoprotein cholesterol (HDL-C), primarily used for dyslipidemia management[3][4]. - **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol biosynthesis in the liver by competitively inhibiting HMG-CoA reductase. This leads to decreased LDL cholesterol and triglycerides while modestly increasing HDL cholesterol[6][8]. The combination may be considered in patients with complex cardiovascular risk profiles requiring anticoagulation alongside intensive lipid-lowering therapy. However, there are clinically significant drug-drug interactions among these agents—particularly increased bleeding risk when warfarin is combined with statins like rosuvastatin—and potential for muscle-related toxicity when combining statins with fibrates such as fenofibric acid[3][5]. Clinical monitoring and dose adjustments are often required.